Entecavir — chronic HBV antiviral suppression

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-ENTECAVIR`

ID	`REG-HBV-ENTECAVIR`
Type	Regimen
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-AASLD-HBV-2024` `SRC-AASLD-HCC-2023` `SRC-EASL-HBV-2025`

Notes

First-line nucleoside analog for chronic HBV suppression. Achieves HBV-DNA undetectability in >95% of treatment-naive patients over 12 months. Long-term suppression reduces HCC incidence by ~50% (HR 0.5, AASLD 2024). Combined with q6mo HCC surveillance (US + AFP) for full cancer-prevention benefit. Discontinuation requires hepatologist consultation due to severe hepatic flare risk.

Used By

Access Pathways

AP-ENTECAVIR-NSZU-HBV - Entecavir via НСЗУ HBV programme (reimbursed)

Contraindications

CI-ENTECAVIR-HIV-MONOTHERAPY - CI-ENTECAVIR-HIV-MONOTHERAPY

Indication

IND-CHRONIC-HBV-PREVENTION-ANTIVIRAL - IND-CHRONIC-HBV-PREVENTION-ANTIVIRAL